Taken together, our results demonstrate the important role of METTL3-IGF2BP3, an m6A modification-recognition regulation combination, in activating the TGF-β/Smads signaling pathway by promoting the stability of EMP1 mRNA and upregulating the expression of EMP1 in pancreatic cancer. Here, IGF2BP3 is linked to familial pancreatic carcinoma.